Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PIMECROLIMUS vs ASTAGRAF XL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pimecrolimus is a calcineurin inhibitor that binds to macrophilin-12 (FKBP-12) and inhibits calcineurin-dependent T-cell activation, thereby suppressing pro-inflammatory cytokine production (e.g., IL-2, IFN-γ) and mast cell degranulation.
Calcineurin inhibitor that binds to FKBP-12, forming a complex that inhibits calcineurin, thereby preventing dephosphorylation and nuclear translocation of NFAT, which reduces T-cell activation and cytokine production (e.g., IL-2).
Mild to moderate atopic dermatitis in immunocompetent patients aged 2 years and older,Off-label: psoriasis, seborrheic dermatitis, vitiligo, lupus erythematosus
Prophylaxis of organ rejection in kidney transplant recipients,Prophylaxis of organ rejection in liver transplant recipients,Prophylaxis of organ rejection in heart transplant recipients
Topical: Apply a thin layer of 1% cream to affected areas twice daily. Maximum daily dose: not established; usual amount is pea-sized per application. Not for continuous long-term use; intermittent use only.
Initial oral dose of 0.1-0.15 mg/kg/day divided every 12 hours, with subsequent adjustments based on trough levels. Typical maintenance dose 0.05-0.15 mg/kg/day.
Terminal elimination half-life is approximately 65 hours (range 22–115 hours) in adult atopic dermatitis patients, reflecting slow systemic clearance.
Terminal elimination half-life is approximately 43 hours (range 15.8–68.6 hours) in adult kidney transplant recipients. This long half-life supports once-daily dosing. In liver transplant patients, half-life ranges from 12 to 42 hours.
Primarily metabolized via hepatic cytochrome P450 3A4 (CYP3A4) to O-demethylated metabolites; also undergoes further hydroxylation and glucuronidation.
Primarily hepatic via CYP3A4 and CYP3A5; undergoes extensive first-pass metabolism. Substrate of P-glycoprotein.
Primarily fecal (78.4% of dose) via biliary excretion; renal elimination accounts for <1% of unchanged drug.
Primarily fecal (94.6%) via biliary elimination. Renal excretion accounts for approximately 2.4% of the dose, mainly as metabolites. Less than 1% is excreted unchanged in urine.
99.5% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 1.3 L/kg (range 0.6–2.1 L/kg), indicating extensive tissue distribution.
Volume of distribution is 3.5–4.5 L/kg (wide distribution, indicating extensive tissue binding). High Vd reflects distribution into erythrocytes, lymphocytes, and tissues.
Topical: Systemic bioavailability is very low (<0.5% of applied dose) based on blood concentration measurements.
Oral bioavailability is highly variable, approximately 20–30% (range 5–89%). Absorption is incomplete and inconsistent; food decreases absorption by up to 33%. The modified-release formulation (Astagraf XL) has a lower peak and more sustained absorption compared to immediate-release.
No dose adjustment required for renal impairment; systemic absorption is minimal (<2.5%).
For GFR <30 m L/min: reduce dose by 50% and monitor trough levels closely. No adjustment for GFR >30 m L/min.
No formal studies in hepatic impairment; based on minimal systemic absorption, no adjustment is likely required, but use caution in severe hepatic impairment due to theoretical risk of increased exposure.
Child-Pugh Class A: no adjustment. Class B: reduce dose by 25%. Class C: reduce dose by 50% and monitor trough levels frequently.
Children ≥2 years: Apply a thin layer of 1% cream to affected areas twice daily; maximum application area: <20% body surface area. Avoid use in children <2 years due to risk of systemic effects (insufficient data).
Initial oral dose 0.15-0.2 mg/kg/day divided every 12 hours. Adjust to target trough levels of 5-15 ng/m L. Maximum dose 0.3 mg/kg/day.
No specific dose adjustment; use lowest effective amount due to potential for increased skin sensitivity and renal function decline with age.
Start at lower end of adult dosing range (0.05 mg/kg/day) and titrate slowly due to reduced renal function and increased risk of adverse effects. Monitor trough levels closely.
Long-term safety of topical calcineurin inhibitors has not been established; rare cases of malignancy (e.g., lymphoma, skin cancer) have been reported; avoid continuous long-term use; limit use to indicated short-term and intermittent treatment.
Increased susceptibility to infection and possible development of lymphoma and other malignancies, particularly of the skin, due to immunosuppression. Increased nephrotoxicity, especially when used with other nephrotoxic drugs.
Increased risk of infections (e.g., varicella zoster, herpes simplex); avoid use on active infections; possible lymphadenopathy; photosensitivity (avoid UV exposure); monitor for skin atrophy; not recommended in children <2 years; use during pregnancy only if clearly needed.
Nephrotoxicity, neurotoxicity (tremor, headache, seizures), hypertension, hyperkalemia, hyperglycemia, increased risk of infections and malignancies (especially skin), and lymphoproliferative disorders. Monitor blood pressure, renal function, electrolytes, and drug levels.
History of hypersensitivity to pimecrolimus or any component of the formulation; Netherton syndrome; generalized erythroderma; active viral, bacterial, or fungal skin infections at application site.
Hypersensitivity to tacrolimus or any component of the formulation; concurrent use with cyclosporine or other calcineurin inhibitors.
No known food interactions with topical pimecrolimus. Oral ingestion should be avoided; however, accidental small amounts on skin are unlikely to cause systemic effects.
Grapefruit juice significantly increases tacrolimus AUC and Cmax; avoid concurrent use. High-fat meals may decrease absorption; maintain consistent fat intake with each dose to ensure stable levels. Avoid taking with alcohol or herbal supplements like St. John's wort, which may reduce efficacy.
Pimecrolimus is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and fetotoxicity at doses 35 times the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to the fetus. First trimester: theoretical risk due to systemic absorption; avoid if possible. Second and third trimesters: limited data; risk of fetal harm cannot be excluded.
Tacrolimus is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, tacrolimus caused maternal toxicity and embryotoxicity at doses higher than those used clinically. First trimester exposure is associated with an increased risk of congenital anomalies, including cardiac malformations. Second and third trimester use has been linked with intrauterine growth restriction, preterm delivery, and transient neonatal hyperkalemia and renal dysfunction. Postnatal immunosuppression in the neonate may occur.
It is not known whether pimecrolimus is excreted in human milk. Systemic absorption after topical application is minimal (<2.5 ng/m L), suggesting negligible transfer. However, due to potential for serious adverse reactions in nursing infants, caution should be exercised. M/P ratio is not available. Breastfeeding is generally considered acceptable with cautious use.
Tacrolimus is excreted into human breast milk with a milk-to-plasma (M/P) ratio of approximately 0.3. Limited data suggest low infant exposure (relative infant dose 0.5% of maternal weight-adjusted dose). However, because of potential for infant immunosuppression and growth effects, breastfeeding is generally not recommended unless benefits outweigh risks. Monitor infant for trough levels if breastfeeding.
No specific dose adjustments are recommended based on pharmacokinetic changes in pregnancy. Use the minimum amount necessary to control symptoms, and avoid application to large body surface areas or prolonged use. Systemic absorption is minimal and unlikely to be altered significantly during pregnancy.
Pregnancy increases tacrolimus clearance due to expanded plasma volume and altered cytochrome P450 3A4 activity. Dose requirements may increase by 25-50% during the second and third trimesters. Therapeutic drug monitoring is essential, targeting trough levels 5-10 ng/m L. Postpartum, doses should be reduced to prepregnancy levels within 1-2 weeks as clearance normalizes.
Pimecrolimus is a topical calcineurin inhibitor used for mild-to-moderate atopic dermatitis. It is not indicated for use in children under 2 years. Avoid use on infected skin; monitor for local irritation. Long-term safety concerns include potential increased risk of lymphoma and skin malignancies; use minimal amounts for shortest duration necessary. Do not use with occlusive dressings. Consider intermittent therapy for flares.
Monitor trough levels 5-15 ng/m L; avoid using with sirolimus due to increased risk of thrombotic microangiopathy; conversion from tacrolimus immediate-release is 1:1 (mg:mg) but monitor levels closely for 2 weeks; administer consistently with or without food to avoid fluctuations.
Apply a thin layer only to affected areas, avoiding eyes, mouth, and broken skin.,Do not cover treated area with bandages or wraps unless directed by your doctor.,Wash hands after applying unless treating hands.,Avoid sun exposure, tanning beds, and UV therapy while using this medication.,Report any signs of infection, skin burning, or worsening rash.,Do not use for prolonged periods; use only until symptoms clear.,Inform your doctor if you are pregnant, breastfeeding, or have a weakened immune system.
Take at the same time every day, consistently with or without food.,Do not crush, chew, or split the extended-release capsules; swallow whole.,Avoid grapefruit and grapefruit juice as they can increase drug levels and toxicity.,Report signs of infection (fever, sore throat), tremors, or changes in urine output immediately.,Minimize sun exposure and use sunscreen due to increased risk of skin cancer.,Do not change brand or formulation without consulting your transplant team.,Keep all appointments for blood level monitoring.
"Pimecrolimus, a calcineurin inhibitor, and panobinostat, a histone deacetylase inhibitor, both have immunosuppressive and potential myelosuppressive effects. Concurrent use may synergistically increase the risk of infections, including opportunistic infections, and hematologic toxicities such as neutropenia, thrombocytopenia, and anemia. Additionally, both drugs can prolong the QT interval, potentially increasing the risk of serious cardiac arrhythmias like torsade de pointes."
"Pimecrolimus, a calcineurin inhibitor used topically, can inhibit CYP3A4 activity to a mild degree, potentially decreasing the metabolism of nilotinib, a BCR-ABL tyrosine kinase inhibitor that is predominantly metabolized by CYP3A4. This may lead to increased nilotinib plasma concentrations, elevating the risk of QT interval prolongation, hepatotoxicity, and other dose-related adverse effects. Therefore, patients should be carefully monitored for signs of nilotinib toxicity."
"Pimecrolimus and sirolimus both suppress immune function via distinct but overlapping mechanisms. Pimecrolimus inhibits calcineurin, reducing T-cell activation, while sirolimus inhibits mTOR, blocking cytokine-driven T-cell proliferation. Concomitant use increases the risk of over-immunosuppression, leading to higher susceptibility to infections, lymphoproliferative disorders, and possibly nephrotoxicity."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PIMECROLIMUS vs ASTAGRAF XL, answered by our medical review team.
PIMECROLIMUS is a Calcineurin Inhibitor that works by Pimecrolimus is a calcineurin inhibitor that binds to macrophilin-12 (FKBP-12) and inhibits calcineurin-dependent T-cell activation, thereby suppressing pro-inflammatory cytokine production (e.g., IL-2, IFN-γ) and mast cell degranulation.. ASTAGRAF XL is a Immunosuppressant, Calcineurin Inhibitor that works by Calcineurin inhibitor that binds to FKBP-12, forming a complex that inhibits calcineurin, thereby preventing dephosphorylation and nuclear translocation of NFAT, which reduces T-cell activation and cytokine production (e.g., IL-2).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PIMECROLIMUS and ASTAGRAF XL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PIMECROLIMUS is: Topical: Apply a thin layer of 1% cream to affected areas twice daily. Maximum daily dose: not established; usual amount is pea-sized per application. Not for continuous long-term use; intermittent use only.. The standard adult dose of ASTAGRAF XL is: Initial oral dose of 0.1-0.15 mg/kg/day divided every 12 hours, with subsequent adjustments based on trough levels. Typical maintenance dose 0.05-0.15 mg/kg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PIMECROLIMUS and ASTAGRAF XL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PIMECROLIMUS is classified as Category A/B. Pimecrolimus is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and fetotoxicity at doses 35 times the maximum recommended human dose. There are no. ASTAGRAF XL is classified as Category C. Tacrolimus is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, tacrolimus caused maternal toxicity an. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.